JP Morgan Chase’s Prothena Corp PRTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-249,900
Closed -$15.2M 6902
2022
Q3
$15.2M Hold
249,900
﹤0.01% 1799
2022
Q2
$6.79M Buy
249,900
+116,100
+87% +$3.4M ﹤0.01% 2497
2022
Q1
$4.89M Buy
+133,800
New +$4.82M ﹤0.01% 3021

Other funds holding PRTA

JP Morgan Chase's PRTA Position: Q1 2026 in Review

JP Morgan Chase reduced its Prothena Corp (PRTA) stake by 85% in Q1 2026, selling an estimated $1.32M and leaving 25,967 shares worth $240K. The position accounts for ﹤0.01% of the portfolio, ranked #5394.

JP Morgan Chase first reported a position in PRTA in Q3 2013 and has held it in 48 quarters since. The position peaked at $28.3M in Q2 2023. 185 funds tracked by Wall St. Rank hold PRTA as of Q1 2026.

  • JP Morgan Chase held 25,967 shares of Prothena Corp worth $240K as of Q1 2026.
  • JP Morgan Chase sold 143,988 Prothena Corp shares in Q1 2026, an estimated $1.32M.
  • Prothena Corp made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5394 holding.
  • JP Morgan Chase first reported a position in Prothena Corp in Q3 2013 and has held it in 48 quarters since.
  • JP Morgan Chase's Prothena Corp position peaked at $28.3M in Q2 2023.
  • 185 funds tracked by Wall St. Rank held Prothena Corp as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.